398 related articles for article (PubMed ID: 30445930)
21. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.
Mohan M; Susanibar-Adaniya S; Buros A; Crescencio JCR; Burgess MJ; Lusardi K; Davies F; Morgan G; Vanrhee F; Zangari M; Schinke C; Thanendrarajan S; Kothari A
Transpl Infect Dis; 2019 Apr; 21(2):e13052. PubMed ID: 30689291
[TBL] [Abstract][Full Text] [Related]
22. Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?
Marchesi F; Pimpinelli F; Di Domenico EG; Renzi D; Gallo MT; Regazzo G; Rizzo MG; Gumenyuk S; Toma L; Marino M; Cordone I; Cantonetti M; Liberati AM; Montanaro M; Ceribelli A; Prignano G; Palombi F; Romano A; Papa E; Pisani F; Spadea A; Arcese W; Ensoli F; Mengarelli A
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893777
[TBL] [Abstract][Full Text] [Related]
23. Changes in the microbiological epidemiology of febrile neutropenia in autologous stem cell transplant recipients.
Rönkkö R; Juutilainen A; Koivula I; Vänskä M; Nousiainen T; Jantunen E; Hämäläinen S
Infect Dis (Lond); 2018 Jun; 50(6):436-442. PubMed ID: 29303041
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma.
Cox JE; Campos S; Wu J; May R; Liu H; Ramos CA; Carrum G; Heslop HE; Brenner MK; Kamble RT
Bone Marrow Transplant; 2014 Feb; 49(2):219-22. PubMed ID: 24096822
[TBL] [Abstract][Full Text] [Related]
25. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Leger C; Sabloff M; McDiarmid S; Bence-Bruckler I; Atkins H; Bredeson C; Zhang H; Huebsch L
Ann Hematol; 2006 Oct; 85(10):723-9. PubMed ID: 16832675
[TBL] [Abstract][Full Text] [Related]
26. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma.
Auner HW; Sill H; Mulabecirovic A; Linkesch W; Krause R
Ann Hematol; 2002 Jul; 81(7):374-7. PubMed ID: 12185506
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
28. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
Bhatt VR; Loberiza FR; Jing H; Bociek RG; Bierman PJ; Maness LJ; Vose JM; Armitage JO; Akhtari M
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):409-415.e1. PubMed ID: 25816932
[TBL] [Abstract][Full Text] [Related]
29. Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma.
Ferrara F; Palmieri S; Viola A; Copia C; Schiavone EM; De Simone M; Pocali B; D'Amico MR; Annunziata M; Mele G
Hematol J; 2004; 5(3):222-6. PubMed ID: 15167908
[TBL] [Abstract][Full Text] [Related]
30. Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape.
Borgsten F; Gatopoulou X; Pisini M; Tambour M; Schain F; Jones CV; Kwok KHM; Batyrbekova N; Björkholm M
Eur J Haematol; 2021 Jul; 107(1):92-103. PubMed ID: 33728732
[TBL] [Abstract][Full Text] [Related]
31. Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation.
Mohyuddin GR; Abbasi S; Okoniewski M; McClune B; Abdallah AO; Ganguly S; McGuirk J; Shune L
Eur J Haematol; 2020 Nov; 105(5):571-577. PubMed ID: 32662224
[TBL] [Abstract][Full Text] [Related]
32. Does ferritin level affect the outcomes of autologous stem cell transplantation equally in all diseases?
Uysal A; Erkurt MA; Kuku İ; Kaya E; Sarıcı A; Berber İ; Biçim S; Hidayet E; Kaya A; Arslan S; Cırık S
Transfus Apher Sci; 2023 Jun; 62(3):103655. PubMed ID: 36805278
[TBL] [Abstract][Full Text] [Related]
33. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
[TBL] [Abstract][Full Text] [Related]
34. Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study.
Jung J; Choi YS; Lee JH; Lee WS; Kim SH; Park Y; Lee SS; Do YR; Jo JC; Lee JJ; Kim JS; Shin HJ; Shin DY; Yoon SS; Min CK; Kim K; Eom HS;
Int J Hematol; 2020 Jul; 112(1):84-95. PubMed ID: 32449149
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
36. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
[TBL] [Abstract][Full Text] [Related]
37. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.
Koreth J; Cutler CS; Djulbegovic B; Behl R; Schlossman RL; Munshi NC; Richardson PG; Anderson KC; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2007 Feb; 13(2):183-96. PubMed ID: 17241924
[TBL] [Abstract][Full Text] [Related]
38. Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis.
Mian H; Mian OS; Rochwerg B; Foley R; Wildes TM
J Geriatr Oncol; 2020 Jan; 11(1):93-99. PubMed ID: 31153809
[TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
[TBL] [Abstract][Full Text] [Related]
40. Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors.
Sureddi RK; Amani F; Hebbar P; Williams DK; Leonardi M; Paydak H; Mehta JL
Ther Adv Cardiovasc Dis; 2012 Dec; 6(6):229-36. PubMed ID: 23047326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
